Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation by Kuwashiro, Shinya et al.
REGULAR ARTICLE
Telmisartan improves nonalcoholic steatohepatitis in medaka
(Oryzias latipes) by reducing macrophage infiltration
and fat accumulation
Shinya Kuwashiro & Shuji Terai & Toshiyuki Oishi &
Koichi Fujisawa & Toshihiko Matsumoto &
Hiroshi Nishina & Isao Sakaida
Received: 7 September 2010 /Accepted: 12 January 2011 /Published online: 16 February 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract We investigated the efficacy of the antihypertensive
drug telmisartan (Tel) and the mechanisms underlying the
progression from simple steatosis to nonalcoholic steatohepa-
titis (NASH) in a medaka (Oryzias latipes) NASH model. We
used the NASH activity score (NAS) developed in humans to
assess the histology of the medaka NASH model and found
that NAS increased with time. Further, TUNEL-positive
apoptosis hepatocytes were found in the medaka NASH
model. Tel administration resulted in the increased expression
of liver peroxisome proliferator-activated receptor-γ, carnitine
palmitoyltransferase 1 and acyl-CoA oxidase 1 and decreased
the number of 8-hydroxydeoxyguanosine-positive hepato-
cytes and the migration of macrophages positive for diastase-
periodic-acid-Schiff. Medaka NAS was improved by Tel
administration but fatty acid content was not affected. Tel





ACC acetyl CoA carboxylase
ACO acyl-CoA oxidase
BMI body mass index
CCR2 CC chemokine receptor 2
CPT carnitine palmitoyltransferase
D-PAS diastase-periodic-acid-Schiff
FAS fatty acid synthase
HE haematoxylin and eosin
HFD high-fat diet
MCP1 monocyte chemotactic protein 1
MNAS medaka NAS
NAFLD nonalcoholic fatty liver disease
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The number of patients worldwide with nonalcoholic fatty
liver disease (NAFLD) has been increasing in recent years.
NAFLD is defined as fatty liver (steatosis) occurring in the
absence of a history of alcohol abuse. NAFLD is closely
linked to obesity, diabetes, hyperlipidaemia and insulin
resistance and is considered to represent a hepatic manifes-
tation of metabolic syndrome (Powell et al. 1990; Sanyal
2002). NAFLD can be classified into either nonprogressive
simple steatosis or nonalcoholic steatohepatitis (NASH)
with inflammation, ballooning degeneration and fibrosis
(Schaffner and Thaler 1986; Younossi et al. 1998). NASH
is a progressive chronic liver disease that can develop into
cirrhosis of the liver and liver cancer; it occurs with high
frequency in obese individuals and in type 2 diabetes
patients and is thought to represent a hepatic manifestation
of metabolic syndrome. No effective treatments have yet been
established for NASH, and the mechanisms underlying the
progression from simple steatosis to NASH have not been
fully clarified.
Previous studies of NASH have made extensive use of
murine models such as mice or rats but the use of small fish
such as zebrafish (Danio rerio) is now common. Medaka
(Oryzias latipes) is a small fish, like zebrafish (Chu and
Chiu 2008;T e r a i2010), that is found in Japan and
continental Asia. Numerous pure medaka bloodlines have
been used in Japan as model animals (Masahito et al. 1989).
Compared with murine models, medaka is highly fecund,
rapidly maturing, and small, thus reducing cost and space
requirements. Further, the mapping of the medaka genome
has been completed and methods for producing transgenic
and knockout individuals have been established, fulfilling
the requirements of an animal model (Kasahara et al. 2007).
We have previously observed that feeding medaka a high-
fat diet (HFD) results in liver histology resembling that of
human NASH and we have reported this as a novel medaka
NASH model (Matsumoto et al. 2010). Administration of
n3 polyunsaturated fatty acids (n3 PUFAs) to this medaka
NASH model ameliorates steatosis, indicating that this
model is useful for the investigation of drug effectiveness
(Matsumoto et al. 2010). Mutant lines with liver steatosis
have been developed in zebrafish (foie gras mutant) and
medaka (Kendama mutant) with forward genetic screening
by using N-ethyl-N-nitrosourea treatment (Sadler et al.
2005; Watanabe et al. 2004). Medaka fish and zebrafish
will be good models for the analysis of NASH pathology
but, at present, our developed medaka NASH model is
the only one to show similarity with human NASH
(Matsumoto et al. 2010).
In the present study, we have used the medaka NASH
model to investigate the efficacy of the antihypertensive drug
telmisartan (Tel). This drug blocks angiotensin II type 1
receptors, excites peroxisome proliferator-activated receptor
(PPAR)-γ and has been reported to improve glycolipid
metabolism. We have also found that Tel administration
ameliorates hepatic fibrosis induced in a model fed with a
choline-deficient L-amino-acid-defined diet (Jin et al. 2007).
NASH progression can be evaluated in clinical settings by
means of the NAFLD activity score (NAS); this score (more
precisely termed the medaka NAS; MNAS) has been
employed in the present study to examine the pathological
condition presented by NASH and to clarify changes in
this condition. We have used the medaka NASH model
to investigate the involvement of macrophages in the
progression of NASH pathology.
Materials and methods
Animals and diets
Himedaka Cab fish (an orange-red variety of medaka) at
8 weeks old were used for most experiments. Fish were
maintained in accordance with the Animal Care Guidelines
of Yamaguchi University. During experiments, fish in
groups of 10 were kept in tap water in plastic tanks covered
with plastic covers and illuminated with fluorescent light
from 08:00 to 22:00. Temperature was controlled at 26±1°C.
Each tank was supplied with 200 mg food, daily, and all
provided food was consumed within 14 h. The energy content
of the control diet (Hikari Crest; Kyorin, Hyogo, Japan) was
3.3 kcal/g with 25.3% from fat, 62.5% from protein and
13.8% from carbohydrates, plus vitamins and minerals as
recommended. The energy content of the HFD (HFD32;
CLEA Japan, Tokyo, Japan) was 5.1 kcal/g with 56.7% from
fat, 20.1% from protein and 23.2% from carbohydrates, plus
vitamins and minerals as recommended. The fatty acid
composition was as shown previously with a ratio of n3/n6
PUFAs of 0.02 (Matsumoto et al. 2010). Tel was dissolved in
dimethyl sulfoxide to a concentration of 2 mg/ml prior to
administration to the test tank at a final concentration of
1m g / l .
Tissue collection and histology
Fish were killed and opened from the anal vent to the gills.
The entire body was fixed with 4% paraformaldehyde in
0.1 M phosphate buffer (PB). The liver was dissected,
dehydrated in alcohol and embedded in paraffin according to
routineprocedures.Serialsectionsweremadeatathicknessof
3-5 μm. Staining was performed by using haematoxylin and
eosin (HE). The number of diastase-periodic-acid-Schiff
(D-PAS)-positive cells per liver section (a single field of view
at 400× magnification) was used to assess macrophage
infiltration with inflammation (Brunt 2001).
126 Cell Tissue Res (2011) 344:125–134Immunohistochemical examination and TUNEL assay
CD68 as a marker for macrophages and 8-hydroxydeoxy-
guanosine (8-OHdG) for the detection of oxidative stress
were immunohistochemically assessed by using the avidin-
biotin-peroxidase complex method, as described previously
(Kolak et al. 2007; Sakaida et al. 1994). The TUNEL
(terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling) assay was performed by using a
commercially available kit (In Situ Cell Death Detection
Kit; Roche Diagnostics, Indianapolis, Ind., USA) according
to the manufacturer’s instructions. Hepatocyte apoptosis in
liver sections was quantified by counting the number of
TUNEL-positive cells in random microscopic low-power
fields (×100).
Blood analysis
Blood samples were obtained from medaka following a
1 2 - hf a s t .F i s hw e r ek e p to ni c ef o r1 –2m i na n dt h e n
bled by cutting a ventral portion of the tail fin. Blood
was collected in a microcapillary tube and the collected
volume was measured. Blood samples were kept at room
temperature for 1 h before centrifugation at 1200g for
30 min at 4°C. Serum triglyceride concentrations were
measured by using a Fuji Drychem 3500 auto-analyser
(Fujifilm, Tokyo, Japan). Cholesterol and triglyceride
(TG) profiles in total lipoproteins were analysed by means
of a dual-detection high-performance liquid chromatogra-
phy system with two tandem-connected TSK gel Lip-
opropakXL columns (300×7.8 mm; Tosoh, Tokuyama,
Japan) by Skylight Biotech (Akita, Japan).
Fatty acid analysis
The fatty acid composition of homogenized liver tissue
(20 mg tissue/ml saline) was determined by capillary gas
chromatography. Total lipids were extracted by using the
procedure described by Folch et al. (1957) and fatty acids
were methylated with boron trifluoride and methanol.
Methylated fatty acids were analysed by using a GC-17A
gas chromatograph (Shimadzu, Kyoto, Japan) equipped
with a BPX70 capillary column (0.25 mm internal
diameter×30 mm; SGE International, Melbourne, Australia).
Tricosanoic acid (C23:0) was used as the internal standard.
The minimum detectable fatty acid concentration detected by
this assay was 0.5 μg/ml.
Semi-quantitative real-time polymerase chain reaction
To avoid the acute effects of food intake, fish were fasted
overnight prior to being killed. Total RNA was extracted
from resections of the liver and purified by using the
RNeasy kit (Qiagen, Hilden, Germany). Next, cDNAs were
synthesized by using purified RNA with random hexamers
in the Transcriptor First Strand cDNA synthesis kit (Roche,
Indianapolis, Ind., US). Semi-quantitative real-time (RT)
polymerase chain reaction (PCR) was performed with PCR
master mix (Promega, Madison, Wis., US) and the primers
are listed in Table 1. Gene expression levels were normalized
against β-actin as an endogenous positive control; acetyl-
CoA carboxylase (ACC) 1, carnitine palmitoyltransferase
(CPT) 1, acyl CoA oxidase (ACO) 1, PPAR-γ and fatty acid
synthase (FAS) were analysed.
Statistical analyses
Numerical data are expressed as the mean±standard
deviation. Student’s t-test was performed to assess statisti-
cal significance among treatment groups. Differences were
considered significant at P<0.05.
Results
Development of steatosis and inflammation of liver tissue
in medaka NASH model and NAS evaluation
Medaka in the HFD group had a higher body weight and
body mass index (BMI) than the control group fed on a
normal diet. Gross evaluation of the liver showed a whitish
hue developing over time in the HFD group (Fig. 1).
Hepatic steatosis was assessed by scoring HE-stained liver
sections. A three-stage scoring system was used: mild
(score 1), fat development confined to the areas surrounding
blood vessels; moderate (score 2), midway between mild and







Table 1 Lists of primers for
selected genes (ACC1 acetyl-
CoA carboxylase 1, ACO1 acyl
CoA oxidase 1, CPT1 carnitine
palmitoyltransferase 1, FAS fatty
acid synthase, PPAR-γ peroxi-
some proliferator-activated
receptor-γ)
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after 4 weeks of HFD administration was 1.5±0.8, which
increased to 2.6±0.8 after 8 weeks, indicating the progression
of steatosis. The number of D-PAS-positive cells was 0.6±0.2
after4weeksofHFDadministrationandreached4.7±1.3after
8 weeks, showing a clear increase in inflammatory cell
infiltration (Fig. 2a-h).
In clinical settings, the recommendation has been made to
distinguish NASH from simple steatosis by using the findings
of NAS, which is based on the degree of steatosis, hepatocyte
ballooning and lobular inflammation. We adapted NAS to
medakabyemployingtheMNAS(scoringcriteriasummarized
in Table 2). Steatosis was scored according to the three-stage
scoring system described above. Lobular inflammation was
scored by assigning a score scheme according to the number
of D-PAS-positive cells per tissue section (single field of
view at 400× magnification). Hepatocyte ballooning was
scored as 1 for a small number of cells showing ballooning
and 2 for a marked number of cells showing ballooning.
MNAS was 1.9±0.7 after 4 weeks of HFD administration and
4.9±1.5 after 8 weeks, showing a clear increase over time
(Fig. 2i).
Tel suppresses weight gain in the medaka NASH model
Compared with the HFD group, a lower weight gain was
observed in the Tel group. Likewise, the increase in BMI
was less in the Tel group. A comparison of the gross
appearance of the liver also showed less steatosis in the Tel
group than in the HFD group (Fig. 3).
Tel suppresses development of steatosis and inflammation
in the medaka NASH model and improves MNAS
The histological investigation revealed the deposition of
lipid droplets in hepatocytes after 2 weeks, with lipid
deposition becoming striking and clear cell formation
being found after 4 weeks on the HFD. Degenerated
hepatocytes were found at 8 weeks. In the Tel group
with administration at 1 ppm, hepatic steatosis was
reduced. No mortality or effects on mobility were found
in the Tel group (Fig. 4a-f). Compared with the HFD
group, the Tel group showed ameliorated steatosis and
inflammatory cell infiltration. MNAS was significantly
improved in the Tel group (1.6±0.9 after 4 weeks, 3.8±1.0
after 8 weeks) compared with the HFD group (1.9±0.7
after 4 weeks, 4.9±1.5 after 8 weeks; Fig. 4g).
Blood examination in the medaka NASH model
Measurement of blood levels of TG in the control, HFD
and Tel groups at 4 and 8 weeks showed that TG increased
over time in the HFD and Tel groups compared with the
control group (Table 3). The TG level was slightly higher in
Fig. 1 The high-fat diet (HFD)
group showed a higher body
weight(a) and body mass index
(BMI; b) than the normal diet
(control) group as a result of the
high fat intake. In the HFD
group, distention of the
abdomen increased (c-e) and the
liver showed a more noticeable
whitish hue (f-h) over time
128 Cell Tissue Res (2011) 344:125–134the Tel group than in the HFD group (Fig. 5a). The HFD
and Tel groups both showed clear increases in the amount
of fatty acids in the liver at 4 weeks compared with the
control group. The n3/n6 PUFA ratio was lower in the HFD
and Tel groups than in the control group at 4 weeks but no
differences were observed in the n3/n6 PUFA ratio between
the HFD and Tel groups (Table 4).
Macrophage infiltration and oxidative stress in medaka
NASH liver tissue
D-PAS staining indicated that both inflammatory cells
and macrophages in the liver tissue of the medaka NASH
model increased over time on HFD (Fig. 2h). Further-
more, we observed tissue with locally aggregated hepato-
cyte degeneration in some areas of medaka NASH model
liver tissue. D-PAS-positive cells were found at each
location, with CD68-positive cells at ballooning hepato-
cyte foci (Fig. 5b-d). The HFD group showed many cells
with 8-OHdG-positive nuclei (Fig. 5e, f). Hepatocyte
degeneration resembling cell ballooning, inflammatory
cell (macrophage) infiltration at the same location and
oxidative stress were confirmed as the constituent
elements of NASH pathology in medaka NASH model
liver tissue. A reduced number of CD68-positive cells,
indicating a reduction in oxidative stress, was detected in
the Tel group.
Induction of apoptosis in medaka steatohepatic liver
The number of apoptotic cells was greater in the HFD
group than in the control group from 4 weeks as shown
Table 2 Critera for nonalcoholic fatty liver disease (NAFLD) activity
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Fig. 2 Histological analysis for
nonalcoholic steatohepatitis
(NASH) medaka. Hepatic
steatosis was assessed by
scoring sections of liver stained
by haematoxylin and eosin (HE)
on a three-stage scoring system:
mild (score 1; a); moderate
(score 2; b); severe diffuse
(score 3; c). After 4 weeks of
HFD, the score was 1.5±0.8,
increasing to 2.6±0.8 after
8 weeks, thereby indicating
steatosis progression (P<0.05;
g). D-PAS staining was used to
assess inflammatory cell infil-
tration according to the number
of D-PAS-positive cells per
tissue section (a single field of
view at 400× magnification;
*P<0.05; d-f, h). The medaka
NAS (MNAS) was 1.9±0.7 after
4 weeks of HFD administration
and 4.9±1.5 after 8 weeks,
showing a clear increase in the
score over time (*P<0.05; i).
The scoring system for the three
parameters is summarized in
Table 2
Cell Tissue Res (2011) 344:125–134 129by TUNEL staining (Fig. 6). Apoptotic cells were
observed mainly in the vicinity of blood vessels, such as
the portal veins and other veins, and fewer apoptotic cells
were seen in the Tel group than in the HFD group.
Changes in gene expression
With regard to the mode of action of Tel on the liver,
PPAR-γ mRNA expression increased in the Tel group
(Fig. 7). RT-PCR analysis showed changes in expression
for some genes involved in glycolipid metabolism and the
pathway for de novo synthesis of fatty acids. The
expression of FAS showed no clear changes in the HFD
or Tel groups compared with the control group (Fig. 7),
whereas the ACC1 genes showed reduced expression in
both the HFD and Tel groups compared with the control
group. The expression of CPT1, indicating β-oxidation in
the mitochondria, was higher in the HFD group than in the
control group and was higher still in the Tel group. The
expression of ACO1, indicating β-oxidation in the
peroxisomes, was lower in the HFD group than in the
control group but similar levels of expression were seen
in the Tel and control groups.
Discussion
We have previously reported the creation of a new NASH
model by feeding medaka with an HFD and its use as a
valid model for screening drugs (Matsumoto et al. 2010). In
the present study, we were able to confirm that medaka fed
HFD showed inflated abdomens and white liver and
developed NASH liver (Fig. 1). Histologically, lipid droplet
deposition was found in medaka hepatocytes from 2 weeks
and became more marked with inflamed and degenerated
hepatocytes being present from 4 weeks (Fig. 4). These
results suggested that the medaka model was easily affected
by diet itself. Next, we made a histological assessment of
medaka liver tissue according to MNAS, based on NAS, a
classification system for human NAFLD/NASH pathology
in clinical settings (Kleiner et al. 2005). We confirmed that
MNAS increased over time in the medaka NASH model.
Moreover, liver tissue in the medaka NASH model showed
fat deposition in hepatocytes and, if the hepatocyte
degeneration was interpreted as ballooning, the NAFLD
pathology could be assessed as type 3 according to the
criteria of Matteoni et al. (1999) and could be regarded as
being equivalent to the human NASH histology.
In our study, we have used this model to investigate the
effects of Tel, an antihypertensive drug that acts as a partial
antagonist of PPAR-γ, which has been reported to improve
glycolipid metabolism. Tel has been reported to attenuate
body weight gain and control fatty liver in rat and mouse
NASH models (Benson et al. 2004; Schupp et al. 2005). We
have performed gene expression analysis by using RT-PCR
on medaka liver and found that PPAR-γ gene expression in
the liver is accelerated by Tel administration. This confirms
that Tel also stimulates PPAR-γ in medaka (Fig. 7). NASH
pathology in medaka is ameliorated by Tel administration
(Figs. 1-6), although no changes in the levels of TG or very
low-density lipoprotein have been found in medaka blood.
We have previously shown that n3 PUFA administration
ameliorates medaka NASH and the n3/n6 PUFA ratio
imbalance in liver fatty acid fractions; however, Tel
Fig. 3 Weight gain in the telmi-
sartan (Tel) group was attenuated
compared with that in the HFD
group (a). Likewise, the BMI
increase was also attenuated in
the Tel group compared with the
HFD group (b). A comparison of
the gross appearance of livers
also showed less steatosis in the
Tel group (c–e)t h a ni nt h eH F D
group (Fig. 1c-h)
130 Cell Tissue Res (2011) 344:125–134administration in the present study does not seem to
ameliorate the n3/n6 PUFA ratio imbalance in the liver
(Table 4). Ballooning degeneration is assumed to be related
to changes in the lipid composition of the fatty acid bilayer
in the cellular membrane and to the n3/n6 PUFA ratio.
Although no change in the n3/n6 PUFA ratio of the liver
fatty acid fraction attributable to Tel administration has
been found, Tel ameliorates ballooning degeneration.
The medaka NASH model shows increased liver
tissue infiltration by D-PAS-positive and CD68-positive
macrophages over time from the start of HFD (Figs. 2,
5b-c) but such cellular infiltrations are suppressed by Tel
administration. These results suggest that the ballooning
degeneration of hepatocytes might be closely regulated by
macrophage infiltration. More detailed investigations of
the relationship between ballooning degeneration and
changes in the lipid composition of the fatty acid bilayer
in the cellular membrane are needed.
These observations indicate that progression of NASH
pathology is linked to the infiltration of macrophages into
liver tissue and that Tel is effective as a dietary treatment to
suppresssuchinfiltration.Arecentstudyhassuggestedthatan
increase in the number of macrophages infiltrating adipose
tissue is correlated with obesity (Weisberg et al. 2003).
Activated monocytes have been found in the arterial walls
of humans and other animals with hypertension (Ishibashi et
Fig. 4 Medaka histology
demonstrated lipid droplet
deposition in hepatocytes after
2 weeks of HFD (a). Lipid
deposition in hepatocytes was
striking and clear cell formation
was observed after 4 weeks (b).
Degenerated hepatocytes were
seen at 8 weeks (c). In the Tel
group (1 ppm), hepatic steatosis
was attenuated over the same
period (d–f). In terms of MNAS,
a significant difference was seen
between the Tel group (1.6±0.9
after 4 weeks [Tel4w], 3.8±1.0
after 8 weeks [Tel8w], P<0.05)
and the HFD group (1.9±0.7
after 4 weeks [HFD4w], 4.9±1.5
after 8 weeks [HFD8w],
P<0.05) with the Tel group
showing improved MNAS (Tel
group after 8 weeks at 3.8±1.0
vs HFD group after 8 weeks at
4.9±1.5; *P<0.05; NS
nonsignificant; g)







Normal 407.4 6.0 107.9 38.4 255.1
HFD4w 955.9 179.6 353.0 65.0 358.2
HFD8w 1352.9 303.4 571.8 107.3 370.5
Tel4w 1035.1 188.1 403.2 91.3 352.6
Tel8w 1490.8 267.3 649.0 133.8 440.7
Table 3 Triglyceride (mg/dl)
changes in medaka blood (1
sample=10 fish; HFD high-fat
diet, Tel telmisartan, w week)
Cell Tissue Res (2011) 344:125–134 131al. 2004; Weisberg et al. 2006). Moreover, insulin resistance
and arteriosclerosis are clearly suppressed in CC chemokine
receptor 2 (CCR2)-deficient mice (Ishibashi et al. 2004;
Weisberg et al. 2006). Haukeland et al. (2006)r e p o r tt h a t
serum concentrations of monocyte chemotactic protein 1
(MCP1) begin to increase with simple steatosis, peaking with
NASH. These findings imply that macrophage infiltration
plays an important role in the initiation of metabolic
syndrome. MCP1 induces the migration of mononuclear
leukocytes by combining with complement receptor type 2
(Fox et al. 1997). A recent study has shown that PPAR-γ
agonists inhibit CCR2 expression in mononuclear leukocytes
(Tanaka et al. 2005). Tel has also been reported to suppress
macrophage infiltration by blocking the MCP1/CCR2
pathway in a mouse NASH model (Kudo et al. 2009). In
our medaka NASH model, Tel might suppress macrophage
migration to the liver.
In this medaka NASH model, oxidative stress has been
evaluated by 8-OHdG immunostaining and has been found
to be attenuated by Tel administration (Fig. 5e, f).
Hepatocyte apoptosis has been reported as being the key
to the second “hit” in the progression from simple steatosis
to NASH in human NAFLD and is a significant pathological
characteristic of NASH (Feldstein et al. 2003). Hepatocyte
apoptosis in liver tissue from the medaka NASH model
increases as a result of HFD administration, suggesting that
apoptosis is linked to the progression from simple steatosis
to NASH and disease development in the medaka NASH
model (Fig. 6). One possible underlying mechanism is that
the increased apoptosis is related to oxidative stress caused
by HFD administration. In the present study, the suppression
of apoptosis is greater in the Tel group than in the HFD
group.
With regard to liver lipid metabolism, lipid deposited in
the fatty liver is in the form of TG. This is attributable to
changes in the balance between TG uptake into the liver
and secretion out of the liver and to the balance between
intrahepatic TG synthesis and breakdown. In our medaka
NASH model, the influx of fats into the liver is likely to
increase as a result of HFD; greater intrahepatic TG
deposition is observed in the HFD group compared with
the control group. Whereas no clear difference in FAS is
apparent, the reduced expression of ACC1 in the HFD
group probably indicates the decrease of de novo fatty acid
synthesis pathways even within the relatively short time-
scale of 2–4 weeks. With respect to fatty acid oxidation
pathways (CPT1 and ACO1), HFD administration appears
to increase the oxidation of fatty acids, which is further
Fig. 5 Blood tests for TG were
carried out on the control, HFD
and Tel groups at 4 and 8 weeks
(a). Compared with the control
group, TG increased over time
in the HFD and Tel groups. The
TG level of the Tel group was
slightly higher than that of HFD
group. We observed tissue with
locally aggregated ballooning
hepatocyte degeneration in some
areas of medaka NASH model
liver tissue (b). Cells positive
for diastase-periodic-acid-Schiff
(D-PAS) were found at each
location (d) and cells positivefor
the macrophage immunostain
CD68 were also found (c). The
HFD group showed many more
cells with nuclei positive for
8-hydroxydeoxyguanosine (e)
compared with the Tel group (f)
132 Cell Tissue Res (2011) 344:125–134increased by Tel administration. We have not assessed any
direct changes of TG or lipid content of the liver in this
series of experiments, despite TG deposition being the
primary factor for the formation of fatty liver. However, Tel
ameliorates steatosis in the liver. We have also shown that
CPT1 and ACO1 expression is increased in the liver on
administration of Tel. Thus, the administration of Tel may
induce the β-oxidation of free fatty acids in the liver of
medaka and thereby also contribute to the reduction of TG
in the liver. We consider that this evidence demonstrates the
effectiveness of Tel on TG or the oxidation of lipids.
In this study, we have investigated the pharmaceutical
effectiveness of Tel, including its potential mechanisms of
action. Tel seems to improve NASH, with the inhibition of
macrophage infiltration and oxidative stress in the liver, but
does not affect the n3/n6 PUFA ratio in NASH liver. These
results show that Tel has a different drug effect on NASH
and the n3/n6 PUFA ratio. Thus, the medaka NASH model
is likely to become a significant experimental model for use
in future NAFLD/NASH studies.
In conclusion, we have demonstrated that the medaka
model produced on HFD exhibits the same changes as
those seen in human NASH pathology. Furthermore, our
study confirms that Tel has an effect on this model.
Fig. 6 a Investigation of induction of apoptosis-positive cells in liver
tissue by TUNEL staining. b Same tissue with HE staining. c The
number of apoptotic cells was greater in the HFD group at 8 weeks
than in the control group at 4 weeks (*P<0.05)
Table 4 Fatty acid composition of total lipids in livers of control,
HFD medaka and HFD+Tel medaka (1 sample=10 fish; SFA saturated
fatty acid, MUFA mono-unsaturated fatty acid, PUFA polyunsaturated
fatty acid)
Fatty acid (mol%) Control HFD HFD+Tel
C14 : 0 3.0 16.2 14.3
C16 : 0 48.6 179.4 202.4
C18 : 0 25.8 53.9 55.2
C16 : 1 n-7 3.9 41.7 50.8
C18 : 1 n-9 25.1 514.1 533.9
C20 : 3 n-9 0.7 17.1 16.7
C18 : 2 n-6 11.8 45.0 52.2
C18 : 3 n-6 1.4 28.2 35.3
C20 : 3 n-6 2.3 5.5 3.8
C20 : 4 n-6 11.0 31.9 32.9
C18 : 3 n-3 1.1 1.7 5.2
C20 : 5 n-3 1.8 0.0 1.1
C22 : 6 n-3 62.1 28.8 28.1
Total SFA 78.4 252.5 275.2
Total MUFA 31.3 565.1 591.8
Total PUFA 99.9 164.0 180.5
n-3 PUFA 70.4 32.0 36.1
n-6 PUFA 28.9 114.9 127.7
n-3/n-6 ratio 2.4 0.3 0.3
Total lipid (mg/g tissue) 209.6 981.6 1047.5
Fig. 7 PPAR-γ expression increased in the Tel group. No clear
changes in expression levels of FAS were found in either the HFD or
Telgroups comparedwith thecontrolgroup. ACC1 mRNAexpressionin
both the HFD and Tel groups was lower than in the control group. CPT1
mRNAexpressionwashigherintheHFDgroupthaninthecontrolgroup
andevenhigherintheTelgroup.ACO1expressionwaslowerintheHFD
group than in the control group. The expression levels of ACO1 were
similar in the Tel and control groups (PPAR-γ peroxisome proliferator-
activated receptor-γ, FAS fatty acid synthase, ACC1 acetyl-CoA
carboxylase 1, CPT1 carnitine palmitoyltransferase 1, ACO1 acyl CoA
oxidase 1)
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